Skip to main content
. 2017 Jun 13;6(6):360–366. doi: 10.1530/EC-17-0104

Table 1.

Clinical characteristics of patients with GNRHR mutations.

Family Member (a) Sex Age of diagnosis (years) Clinical presentation Olfaction (b) Associated features Basal hormone levels (laboratory normal reference range) Mutations
1 II-3 M 18.5 Delayed puberty. Micropenis. Tanner stage 3. Testicular volume 3 mL Normal Surgery for right-sided cryptorchidism at age 1.5 years FSH 1.2 IU/mL (1.0–8.0); LH 0.5 IU/mL (0.7–7.2); total testosterone 0.20 ng/mL (2.60–10.00) GNRHR p.[Val134Gly];[Arg139Cys] (compound heterozygous)
2 II-1 M 22 Delayed puberty. Tanner stage 1. Testicular volume 5 mL Normal FSH 2.4 IU/mL (2.5–10.2); LH <0.1 IU/mL (1.9–2.5); total testosterone 0.33 ng/mL (2.60–10.00) GNRHR p.[Gln106Arg];[Phe313Metfs*3] (compound heterozygous)
II-2 F 18 Primary amenorrhea Normal FSH 2.2 IU/mL (2.5–10.2); LH 0.9 IU/mL (1.9–2.5); estradiol 15 pg/mL (11–69) GNRHR p.[Gln106Arg];[Phe313Metfs*3] (compound heterozygous)
3 II-2 M 51 Delayed puberty. Tanner stage 1. Testicular volume 5 mL Normal Low bone mineral density (lumbar spine T-score −2.3; femoral neck T-score −2.8) FSH 1.1 IU/mL (1.0–8.0); LH 0.4 IU/mL (0.7–7.2); total testosterone 0.40 ng/mL (2.70–11.00) GNRHR p.[Arg262Gln];[Phe313Metfs*3] (compound heterozygous)
4 II-2 M n/a n/a n/a n/a GNRHR p.[Tyr283His];[Tyr283His] (homozygous)
II-4 F n/a Primary amenorrhea Normal FSH 0.4 IU/mL (1.5–33.4); LH <0.07 IU/mL (1.7–15.0); estradiol <11.8 pg/mL (19.5–356.7) GNRHR p.[Tyr283His];[Tyr283His] (homozygous)
II-5 F 39 Primary amenorrhea Normal Low bone mineral density (lumbar spine T-score −3.2; femoral neck T-score −1.0). Hypercholesterolemia. Secondary sex characteristics had developed due to oral contraceptive use in adolescence FSH 0.7 IU/mL (4.0–13.0); LH 0.1 IU/mL (1.7–15.0); estradiol <10 pg/mL (20–150) GNRHR p.[Tyr283His];[Tyr283His] (homozygous)
5 II-1 M 15 Delayed puberty. Tanner stage 1. Testicular volume <5 mL Normal Surgery for left-sided cryptorchidism at age 10 years FSH 0.5 IU/mL (1.4–18.0); LH 0.7 IU/mL (1.5–9.3); total testosterone 0.09 ng/mL (2.20–8.00) GNRHR p.Val134Gly (heterozygous) + PROKR2 p.Arg80Cys (heterozygous)

Hormone levels were measured by chemiluminescence immunoassays; bone mineral densities were measured by dual-energy X-ray absorptiometry.

(a) As indicated in Figs 1 and 2; (b) self-reported.

F, female; FSH, follicle-stimulating hormone; LH, luteinising hormone; M, male; n/a, not available.